EA201390370A1 - Молекулярно-диагностический тест для определения онкологического заболевания - Google Patents
Молекулярно-диагностический тест для определения онкологического заболеванияInfo
- Publication number
- EA201390370A1 EA201390370A1 EA201390370A EA201390370A EA201390370A1 EA 201390370 A1 EA201390370 A1 EA 201390370A1 EA 201390370 A EA201390370 A EA 201390370A EA 201390370 A EA201390370 A EA 201390370A EA 201390370 A1 EA201390370 A1 EA 201390370A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- cancer
- therapeutic regimen
- test
- diagnostic test
- molecular diagnostic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/20—Supervised data analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B30/00—Methods of screening libraries
- C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Theoretical Computer Science (AREA)
- Evolutionary Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Epidemiology (AREA)
- Data Mining & Analysis (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Databases & Information Systems (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Evolutionary Computation (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Bioethics (AREA)
- Artificial Intelligence (AREA)
Abstract
Предложены способы и композиции для идентификации молекулярно-диагностического теста на онкологическое заболевание. Тест определяет новый молекулярный подтип дефицита системы репарации повреждений ДНК и проводит классификацию пациента в пределах этого подтипа. Изобретение можно применять для определения того, способен ли пациент с онкологическим заболеванием дать клинический ответ на терапевтический режим или же он не способен дать клинический ответ на терапевтический режим, перед введением какой-либо химиотерапии. Данный тест можно применять при различных типах рака и в отношении различных лекарственных препаратов, которые напрямую или опосредованно воздействуют на повреждение или систему репарации ДНК, таких как многие стандартные цитотоксические химиотерапевтические лекарства, применяемые в настоящее время. В частности, изобретение относится к применению определенных комбинаций прогностических маркеров, при этом экспрессия прогностических маркеров коррелирует со способностью или неспособностью ответить на терапевтический режим.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38320110P | 2010-09-15 | 2010-09-15 | |
US201161490039P | 2011-05-25 | 2011-05-25 | |
PCT/US2011/051803 WO2012037378A2 (en) | 2010-09-15 | 2011-09-15 | Molecular diagnostic test for cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201390370A1 true EA201390370A1 (ru) | 2013-07-30 |
Family
ID=45832248
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201390370A EA201390370A1 (ru) | 2010-09-15 | 2011-09-15 | Молекулярно-диагностический тест для определения онкологического заболевания |
Country Status (16)
Country | Link |
---|---|
US (4) | US9670547B2 (ru) |
EP (2) | EP2619574B1 (ru) |
JP (2) | JP2013537045A (ru) |
KR (1) | KR20130115250A (ru) |
CN (2) | CN103299188B (ru) |
AU (2) | AU2011302004B2 (ru) |
BR (1) | BR112013006207A2 (ru) |
CA (1) | CA2811015A1 (ru) |
EA (1) | EA201390370A1 (ru) |
HK (1) | HK1216665A1 (ru) |
MX (1) | MX344636B (ru) |
MY (1) | MY166040A (ru) |
NZ (3) | NZ712823A (ru) |
SG (2) | SG10201610027VA (ru) |
WO (1) | WO2012037378A2 (ru) |
ZA (2) | ZA201301567B (ru) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5645816B2 (ja) | 2009-05-25 | 2014-12-24 | 国立大学法人東京工業大学 | 中枢神経細胞の増殖及び分化に係る中核因子を含む医薬組成物 |
US9670547B2 (en) | 2010-09-15 | 2017-06-06 | Almac Diagnostics Limited | Molecular diagnostic test for cancer |
CN103688176A (zh) | 2011-04-29 | 2014-03-26 | 细胞基因公司 | 利用cereblon作为预报因子治疗癌和炎性疾病的方法 |
CA2835179A1 (en) * | 2011-05-06 | 2012-11-15 | Xentech | Markers for cancer prognosis and therapy and methods of use |
EA201691257A1 (ru) | 2011-06-02 | 2017-02-28 | Олмак Дайэгностикс Лимитед | Молекулярно-диагностический тест на рак |
EP2723898A4 (en) * | 2011-06-22 | 2015-09-30 | Oncocyte Corp | METHOD AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF BUBBLE CANCER |
MX358517B (es) * | 2012-06-29 | 2018-08-24 | Celgene Corp | Métodos para determinar eficacia de fármacos usando proteínas asociadas a cereblon. |
US9587281B2 (en) | 2012-08-14 | 2017-03-07 | Celgene Corporation | Cereblon isoforms and their use as biomarkers for therapeutic treatment |
AU2013312188A1 (en) * | 2012-09-10 | 2015-03-26 | Celgene Corporation | Methods for the treatment of locally advanced breast cancer |
SG11201504023SA (en) | 2012-12-03 | 2015-06-29 | Almac Diagnostics Ltd | Molecular diagnostic test for cancer |
US9302005B2 (en) | 2013-03-14 | 2016-04-05 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
KR102158924B1 (ko) | 2013-03-15 | 2020-09-22 | 제넨테크, 인크. | Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법 |
AU2014251043B2 (en) * | 2013-04-09 | 2020-01-16 | The Board Of Regents Of The University Of Texas System | Tumor-selective combination therapy |
GB201316024D0 (en) * | 2013-09-09 | 2013-10-23 | Almac Diagnostics Ltd | Molecular diagnostic test for lung cancer |
GB201316027D0 (en) * | 2013-09-09 | 2013-10-23 | Almac Diagnostics Ltd | Molecular diagnostic test for oesophageal cancer |
US10259875B2 (en) | 2013-10-01 | 2019-04-16 | Mayo Foundation For Medical Education And Research | Methods for treating cancer in patients with elevated levels of BIM |
JP2017503503A (ja) * | 2014-01-06 | 2017-02-02 | エクスプレッション、パソロジー、インコーポレイテッド | Pd−l1に対するsrmアッセイ |
GB201409479D0 (en) | 2014-05-28 | 2014-07-09 | Almac Diagnostics Ltd | Molecular diagnostic test for cancer |
EP3137076A4 (en) * | 2014-05-02 | 2017-12-06 | Emory University | Selective chemotherapy treatments and diagnostic methods related thereto |
WO2015179654A1 (en) | 2014-05-22 | 2015-11-26 | Mayo Foundation For Medical Education And Research | Distinguishing antagonistic and agonistic anti b7-h1 antibodies |
JP6640126B2 (ja) | 2014-06-27 | 2020-02-05 | セルジーン コーポレイション | セレブロン及び他のe3ユビキチンリガーゼの立体構造の変化を誘導するための組成物及び方法 |
RU2715038C2 (ru) | 2014-07-11 | 2020-02-21 | Дженентек, Инк. | Антитела анти-pd-l1 и способы их диагностического применения |
US10517875B2 (en) | 2014-07-23 | 2019-12-31 | Mayo Foundation for Medical Engineering and Research | Targeting DNA-PKcs and B7-H1 to treat cancer |
US20180148792A1 (en) | 2015-05-19 | 2018-05-31 | T.S. Sridhar | Method for Identification of a Deficient BRCA1 Function |
GB201512869D0 (en) * | 2015-07-21 | 2015-09-02 | Almac Diagnostics Ltd | Gene signature for minute therapies |
DK3594343T3 (da) | 2015-07-23 | 2021-06-28 | Inst Curie | Anvendelse af en kombination af dbait-molekyle og parp-inhibitorer til behandling af kræft |
JP6624704B2 (ja) | 2015-08-31 | 2019-12-25 | 日立化成株式会社 | 尿路上皮疾患の評価のための分子法 |
JP6991134B2 (ja) | 2015-10-09 | 2022-01-12 | ガーダント ヘルス, インコーポレイテッド | 無細胞dnaを使用する集団ベースの処置レコメンダ |
US10875923B2 (en) | 2015-10-30 | 2020-12-29 | Mayo Foundation For Medical Education And Research | Antibodies to B7-H1 |
WO2017117118A1 (en) | 2015-12-28 | 2017-07-06 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases |
US20170321285A1 (en) * | 2016-05-03 | 2017-11-09 | The Texas A&M University System | Nlrc5 as a biomarker for cancer patients and a target for cancer therapy |
WO2017216559A1 (en) * | 2016-06-14 | 2017-12-21 | Almac Diagnostics Limited | Predicting responsiveness to therapy in prostate cancer |
WO2018083538A1 (en) | 2016-11-07 | 2018-05-11 | Neuracle Scienc3 Co., Ltd. | Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof |
CN108663519A (zh) * | 2017-04-21 | 2018-10-16 | 江苏希摩生物科技有限公司 | 快速预测和提高BRCA1/2野生型卵巢癌细胞对Olaparib敏感性的方法 |
WO2018213141A1 (en) * | 2017-05-16 | 2018-11-22 | Hitachi Chemical Co. America, Ltd. | Methods for detecting ovarian cancer using extracellular vesicles for molecular analysis |
KR102574549B1 (ko) | 2017-06-27 | 2023-09-07 | 주식회사 뉴라클사이언스 | 항-fam19a5 항체 및 이의 용도 |
WO2019003159A1 (en) * | 2017-06-27 | 2019-01-03 | Neuracle Science Co., Ltd. | USE OF ANTI-FAM19A5 ANTIBODIES FOR THE TREATMENT OF FIBROSIS |
EP3645044A4 (en) | 2017-06-27 | 2021-04-28 | Neuracle Science Co., Ltd | USE OF ANTI-FAMILY WITH SEQUENCE SIMILARITY 19, ELEMENT A5 ANTIBODIES TO TREAT GLAUCOMA |
KR20230142819A (ko) * | 2017-06-27 | 2023-10-11 | 주식회사 뉴라클사이언스 | 암 치료를 위한 항-fam19a5 항체의 용도 |
CN110021357B (zh) * | 2017-12-27 | 2021-06-04 | 浙江安诺优达生物科技有限公司 | 模拟癌症基因组测序数据生成装置 |
FR3078343A1 (fr) | 2018-02-27 | 2019-08-30 | Lxrepair | Methode pour generer un profil des capacites de reparation de l'adn de cellules tumorales et ses applications |
CN108379584B (zh) * | 2018-04-12 | 2020-08-11 | 上海交复生物医药科技有限公司 | RSAD2通过wnt通路影响肿瘤细胞替莫唑胺耐药性 |
WO2019207513A1 (en) | 2018-04-24 | 2019-10-31 | Neuracle Science Co., Ltd. | Use of anti-family with sequence similarity 19, member a5 antibodies for the treatment of neuropathic pain |
CN108977547B (zh) * | 2018-08-14 | 2019-05-28 | 江门市中心医院 | Tspan1在乳腺癌转移的诊断、预后及治疗中的应用 |
CN109295208A (zh) * | 2018-10-26 | 2019-02-01 | 德阳市人民医院 | Pi15作为骨关节炎标志物的应用 |
CN109652540A (zh) * | 2018-12-21 | 2019-04-19 | 思泰得精准(北京)医学检验实验室有限公司 | 一种甲状腺癌早期检测分子标志物及其应用 |
KR20240000655A (ko) * | 2018-12-27 | 2024-01-02 | 주식회사 뉴라클사이언스 | 죽상경화증을 치료하기 위한 항-fam19a5 항체의 사용 |
EP3955943A4 (en) * | 2019-02-22 | 2023-10-25 | Candel Therapeutics, Inc. | COMBINATION THERAPY WITH GMCI AND DDRI FOR THE TREATMENT OF CANCER |
CN110570922B (zh) * | 2019-07-19 | 2022-06-10 | 浙江大学 | 一种评估hr缺陷模型及应用 |
WO2021067310A1 (en) * | 2019-09-30 | 2021-04-08 | Candel Therapeutics, Inc. | Combination gmci and atri cancer treatment |
WO2023017525A1 (en) * | 2021-08-11 | 2023-02-16 | OncoHost Ltd. | Predicting patient response |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5525464A (en) | 1987-04-01 | 1996-06-11 | Hyseq, Inc. | Method of sequencing by hybridization of oligonucleotide probes |
US5202231A (en) | 1987-04-01 | 1993-04-13 | Drmanac Radoje T | Method of sequencing of genomes by hybridization of oligonucleotide probes |
GB8810400D0 (en) | 1988-05-03 | 1988-06-08 | Southern E | Analysing polynucleotide sequences |
US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
US5547839A (en) | 1989-06-07 | 1996-08-20 | Affymax Technologies N.V. | Sequencing of surface immobilized polymers utilizing microflourescence detection |
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
EP0430881A3 (en) | 1989-11-29 | 1991-10-23 | Ciba-Geigy Ag | Photochromic compounds, process for their preparation and their use |
US5288644A (en) | 1990-04-04 | 1994-02-22 | The Rockefeller University | Instrument and method for the sequencing of genome |
US5324633A (en) | 1991-11-22 | 1994-06-28 | Affymax Technologies N.V. | Method and apparatus for measuring binding affinity |
ATE173767T1 (de) | 1992-04-03 | 1998-12-15 | Perkin Elmer Corp | Proben zusammensetzung und verfahren |
US5503980A (en) | 1992-11-06 | 1996-04-02 | Trustees Of Boston University | Positional sequencing by hybridization |
US5858659A (en) | 1995-11-29 | 1999-01-12 | Affymetrix, Inc. | Polymorphism detection |
US5470710A (en) | 1993-10-22 | 1995-11-28 | University Of Utah | Automated hybridization/imaging device for fluorescent multiplex DNA sequencing |
GB9401833D0 (en) | 1994-02-01 | 1994-03-30 | Isis Innovation | Method for discovering ligands |
GB9507238D0 (en) | 1995-04-07 | 1995-05-31 | Isis Innovation | Detecting dna sequence variations |
US5661028A (en) | 1995-09-29 | 1997-08-26 | Lockheed Martin Energy Systems, Inc. | Large scale DNA microsequencing device |
JP2002515738A (ja) | 1996-01-23 | 2002-05-28 | アフィメトリックス,インコーポレイティド | 核酸分析法 |
WO1997029212A1 (en) | 1996-02-08 | 1997-08-14 | Affymetrix, Inc. | Chip-based speciation and phenotypic characterization of microorganisms |
DE69823206T2 (de) | 1997-07-25 | 2004-08-19 | Affymetrix, Inc. (a Delaware Corp.), Santa Clara | Verfahren zur herstellung einer bio-informatik-datenbank |
US7324926B2 (en) * | 1999-04-09 | 2008-01-29 | Whitehead Institute For Biomedical Research | Methods for predicting chemosensitivity or chemoresistance |
US20040146921A1 (en) | 2003-01-24 | 2004-07-29 | Bayer Pharmaceuticals Corporation | Expression profiles for colon cancer and methods of use |
JP2007504842A (ja) | 2003-05-29 | 2007-03-08 | ミレニアム ファーマシューティカルズ, インコーポレイテッド | 乳癌の同定、評価、予防、および治療のための組成物、キットおよび方法 |
EP1673470A2 (en) | 2003-09-18 | 2006-06-28 | Genmab A/S | Differentially expressed tumour-specific polypeptides for use in the diagnosis and treatment of cancer |
WO2005054508A2 (en) | 2003-12-01 | 2005-06-16 | Ipsogen | Gene expression profiling of colon cancer by dna microarrays and correlation with survival and histoclinical parameters |
CN1905864B (zh) * | 2003-12-01 | 2011-04-06 | 库多斯药物有限公司 | 用于治疗癌症的dna损伤修复抑制剂 |
NZ547984A (en) * | 2003-12-01 | 2009-03-31 | Kudos Pharm Ltd | DNA damage repair inhibitors for treatment of cancer |
WO2005083440A2 (en) | 2004-02-19 | 2005-09-09 | Yale University | Identification of cancer protein biomarkers using proteomic techniques |
WO2005083128A2 (en) | 2004-02-25 | 2005-09-09 | University Of South Florida | Methods for predicting cancer outcome and gene signatures for use therein |
US20060195266A1 (en) | 2005-02-25 | 2006-08-31 | Yeatman Timothy J | Methods for predicting cancer outcome and gene signatures for use therein |
CA2586201A1 (en) | 2004-11-03 | 2006-05-11 | Almac Diagnostics Limited | Transcriptome microarray technology and methods of using the same |
CA2624086A1 (en) | 2005-09-28 | 2007-04-05 | H. Lee Moffitt Cancer Center | Individualized cancer treatments |
EP1777523A1 (en) | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
US8445198B2 (en) | 2005-12-01 | 2013-05-21 | Medical Prognosis Institute | Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
DK1974058T3 (da) | 2006-01-11 | 2014-09-01 | Genomic Health Inc | Genekspressionsmarkører til prognosticering af kolorektal cancer |
US7892740B2 (en) * | 2006-01-19 | 2011-02-22 | The University Of Chicago | Prognosis and therapy predictive markers and methods of use |
US20070218512A1 (en) | 2006-02-28 | 2007-09-20 | Alex Strongin | Methods related to mmp26 status as a diagnostic and prognostic tool in cancer management |
WO2007112330A2 (en) | 2006-03-24 | 2007-10-04 | Diadexus, Inc. | Compositions and methods for detection, prognosis and treatment of colon cancer |
US8768629B2 (en) | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
KR20090017655A (ko) * | 2006-06-02 | 2009-02-18 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 환자가 면역치료제에 대한 반응자일지의 여부를 확인하는 방법 |
CA2655933C (en) * | 2006-06-23 | 2014-09-09 | Alethia Biotherapeutics Inc. | Polynucleotides and polypeptide sequences involved in cancer |
US20100284915A1 (en) | 2006-06-30 | 2010-11-11 | Hongyue Dai | Genes associated with chemotherapy response and uses thereof |
WO2008066624A2 (en) * | 2006-10-20 | 2008-06-05 | Dana-Farber Cancer Institute | Dna damage repair inhibitors and methods for treating cancer |
AU2008206051A1 (en) | 2007-01-18 | 2008-07-24 | University Of Southern California | Gene polymorphisms as sex-specific predictors in cancer therapy |
EP1961825A1 (en) | 2007-02-26 | 2008-08-27 | INSERM (Institut National de la Santé et de la Recherche Medicale) | Method for predicting the occurrence of metastasis in breast cancer patients |
WO2008132176A2 (en) | 2007-04-27 | 2008-11-06 | Universite Catholique De Louvain | Method for evaluating the response of an individual to tnf blocking therapy |
EP2405022A3 (en) | 2008-07-08 | 2012-05-02 | Genomic Health, Inc. | Gene expression profiling for predicting the survivability of prostate cancer subjects |
WO2010040083A2 (en) | 2008-10-03 | 2010-04-08 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Gene expression predictors of chemoresistance |
WO2010045463A2 (en) | 2008-10-15 | 2010-04-22 | Government Of The United States As Represented By The Secretary Of The Army | Clinical decision model |
WO2010060055A1 (en) | 2008-11-21 | 2010-05-27 | Duke University | Predicting cancer risk and treatment success |
WO2010118782A1 (en) * | 2009-04-17 | 2010-10-21 | Universite Libre De Bruxelles | Methods and tools for predicting the efficiency of anthracyclines in cancer |
WO2011005384A2 (en) * | 2009-05-29 | 2011-01-13 | Baylor College Of Medicine | Dna repair or brca1-like gene signature |
AU2011223789A1 (en) | 2010-03-01 | 2012-09-20 | Caris Life Sciences Switzerland Holdings Gmbh | Biomarkers for theranostics |
CA2801588A1 (en) | 2010-06-04 | 2011-12-08 | Bioarray Therapeutics, Inc. | Gene expression signature as a predictor of chemotherapeutic response in breast cancer |
US9670547B2 (en) | 2010-09-15 | 2017-06-06 | Almac Diagnostics Limited | Molecular diagnostic test for cancer |
-
2011
- 2011-09-15 US US13/821,404 patent/US9670547B2/en active Active
- 2011-09-15 NZ NZ712823A patent/NZ712823A/en not_active IP Right Cessation
- 2011-09-15 MY MYPI2013000762A patent/MY166040A/en unknown
- 2011-09-15 EA EA201390370A patent/EA201390370A1/ru unknown
- 2011-09-15 EP EP11825959.7A patent/EP2619574B1/en active Active
- 2011-09-15 EP EP15181181.7A patent/EP2975399B1/en active Active
- 2011-09-15 AU AU2011302004A patent/AU2011302004B2/en not_active Ceased
- 2011-09-15 CN CN201180047116.5A patent/CN103299188B/zh not_active Expired - Fee Related
- 2011-09-15 KR KR1020137009145A patent/KR20130115250A/ko not_active Application Discontinuation
- 2011-09-15 SG SG10201610027VA patent/SG10201610027VA/en unknown
- 2011-09-15 CA CA2811015A patent/CA2811015A1/en not_active Abandoned
- 2011-09-15 NZ NZ608459A patent/NZ608459A/en not_active IP Right Cessation
- 2011-09-15 JP JP2013529331A patent/JP2013537045A/ja active Pending
- 2011-09-15 NZ NZ620799A patent/NZ620799A/en not_active IP Right Cessation
- 2011-09-15 CN CN201710082290.2A patent/CN106978480A/zh active Pending
- 2011-09-15 WO PCT/US2011/051803 patent/WO2012037378A2/en active Application Filing
- 2011-09-15 MX MX2013002879A patent/MX344636B/es active IP Right Grant
- 2011-09-15 SG SG2013016175A patent/SG188397A1/en unknown
- 2011-09-15 BR BR112013006207A patent/BR112013006207A2/pt not_active Application Discontinuation
-
2013
- 2013-02-28 ZA ZA2013/01567A patent/ZA201301567B/en unknown
- 2013-10-07 US US14/047,949 patent/US9677140B2/en active Active
- 2013-12-23 HK HK16104700.5A patent/HK1216665A1/zh unknown
-
2015
- 2015-08-13 US US14/825,480 patent/US10214777B2/en active Active
- 2015-11-26 ZA ZA2015/08689A patent/ZA201508689B/en unknown
-
2016
- 2016-01-28 AU AU2016200494A patent/AU2016200494B2/en not_active Ceased
- 2016-12-09 JP JP2016238969A patent/JP2017093440A/ja active Pending
-
2017
- 2017-02-07 US US15/426,923 patent/US10378066B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201390370A1 (ru) | Молекулярно-диагностический тест для определения онкологического заболевания | |
MX2016003016A (es) | Pruebas diagnosticas moleculares para cancer pulmonar. | |
EA201391805A1 (ru) | Молекулярно-диагностический тест на рак | |
MX2015006955A (es) | Prueba de diagnostico molecular para cancer. | |
MX2016003077A (es) | Prueba diagnostica molecular para cancer esofagico. | |
BRPI0906858B8 (pt) | métodos in vitro para detectar a presença de uma célula de câncer em um indivíduo e para identificar uma assinatura específica de tumor em um indivíduo tendo câncer. | |
BR112015012014A2 (pt) | proteínas de ligação específicas duais penetrando a barreira hematoencefálica (bbb) | |
PH12018550037A1 (en) | Quencher containing water-soluble polymer-conjugated nanomaterial and use thereof | |
NZ627443A (en) | Biological markers for identifying patients for treatment with vegf antagonists | |
BR112014015152A2 (pt) | métodos e materiais para a avaliação da perda de heterozigosidade | |
BR112012017084A2 (pt) | métodos para previsão de resposta de câncer de mama triplo-negativo à terapia | |
WO2014036387A3 (en) | Methods for diagnosis and treatment of cancer | |
BR112015012644A2 (pt) | método para determinar a necessidade de um paciente com câncer, método de tratamento do câncer, composição farmacêutica, uso de um ácido nucleico ou anticorpo e kit; | |
CY1114111T1 (el) | Μεθοδοι χρησης του mirna για την ανιχνευση του in vivo θανατου των κυτταρων | |
EA201500334A1 (ru) | Fgfr3 гибридный ген и лекарственный препарат, нацеленный на него | |
WO2011133668A3 (en) | Methods and compositions for the treatment of cancer | |
NZ612483A (en) | Drug selection for malignant cancer therapy using antibody-based arrays | |
MX2013000916A (es) | Metodos para detectar firmas de enfermedad o condiciones en fluidos corporales. | |
BR112016007864A2 (pt) | método para a prognose e tratamento de metástase de câncer | |
TR201903026T4 (tr) | S100a4 anti̇korlari ve bunlarin terapöti̇k kullanimlari. | |
MX2015001716A (es) | Niclosamida para el tratamiento de tumores solidos. | |
NZ603780A (en) | Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer | |
BR112015022055A2 (pt) | gestão de transições de área de cuidado de infusões intravenosas | |
BR112015008257A2 (pt) | marcadores para diagnóstico molecular prdm14 e fam19a4 para cânceres invasivos induzidos por hpv e suas lesões precursoras de alto grau | |
BR112013008573A2 (pt) | citocinas biomarcadoras como indicadores de resposta clínica a acetato de glatirâmer. |